INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 430m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN30m ago
SEC FORM 4/Other acquisition or dispositionVerified data

Luo Yuling reported ALMR

Director, Chief Executive Officer · Alamar Biosciences, Inc. · Class B Common Stock

Side
J
Value
—
Shares
1.86M
Price
—
Executed
Apr 20, 2026
Disclosed
Apr 20, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Apr 20 executedApr 20, 2026 disclosed

ALMR · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
12/ 100 · ROUTINE
Methodology →
  • Transaction type+3 / 20

    Other acquisition or disposition

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALMR

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    20
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$504K
    16.9K sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    23
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$2.16M
    72.3K sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    17
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$58K
    1,946 sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    20
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$604K
    20.2K sh
    		Nov 3, 2026Nov 5, 2026
    traded Nov 3, 2026
    		+2dSEC FORM 4

    Evidence

    20
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$197K
    7,415 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    20
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$55K
    2,072 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    17
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$5,326
    200 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    20
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$83K
    2,904 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    23
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$565K
    20.2K sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    30
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$1.29M
    49.0K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    27
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$301K
    11.4K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    20
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$54K
    1,947 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    21
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$35K
    1,320 sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    23
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$354K
    12.4K sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    27
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$361K
    13.7K sh
    		Oct 19, 2026Oct 21, 2026
    traded Oct 19, 2026
    		+2dSEC FORM 4

    Evidence

    26
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$2.02M
    72.4K sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    23
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$472K
    16.9K sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    17
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$9,527
    335 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    17
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$46K
    1,730 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    20
    QV
    Qiming Corporate GP VI, Ltd.10% Owner
    ALMRAlamar Biosciences, Inc.
    Open-market sale
    		SELL$99K
    3,477 sh
    		Oct 20, 2026Oct 21, 2026
    traded Oct 20, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002126941-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 20, 2026
    Published
    Apr 20, 2026
    Ingested by INSIDER
    Nov 5, 04:03 UTC
    Last re-read
    Nov 5, 04:03 UTC

    Extracted facts

    Filer
    Luo Yuling
    Role
    Director, Chief Executive Officer
    Transaction
    Other acquisition or dispositionAs filed: “J”
    Asset
    Alamar Biosciences, Inc.
    Ticker
    ALMR
    Shares
    1.86M
    Execution date (reported)
    Apr 20, 2026
    Owned after transaction
    0 shares
    Days from execution to publication
    0

    What this establishes

    Luo Yuling filed this Form 4 reporting a other acquisition or disposition of ALMR on Apr 20, 2026. It became public on Apr 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chief Executive Officer
    Luo Yulingcik:0002126941
    Issuer
    Alamar Biosciences, Inc.cik:0002104204

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.